Understanding the costs of care for cystic fibrosis: an analysis by age and health state.
about
Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseasesAn overview of international literature from cystic fibrosis registries. Part 5: Update 2012-2015 on lung disease.Cystic fibrosis on the African continent.Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data.Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.Prenatal and preconception population carrier screening for cystic fibrosis in Australia: where are we up to?Cystic fibrosis: a look into the future of prenatal screening and therapy.A Scoping Review of Healthcare Costs for Patients with Cystic Fibrosis.Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012.Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It?Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation.Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study.Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.Human Bocavirus Type-1 Capsid Facilitates the Transduction of Ferret Airways by Adeno-Associated Virus Genomes.Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients.Preventable spina bifida and anencephaly in Europe.Drug-induced dyspnea versus cystic fibrosis exacerbation: a diagnostic dilemma.National Healthcare Delivery Systems Influence Lung Transplant Outcomes for Cystic Fibrosis.Cost-of-Illness in Rare Diseases.Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe.Innovative assessment of inpatient and pulmonary drug costs for children with cystic fibrosis.
P2860
Q26825799-92FE4AAC-24F1-43DE-922A-B96C41BF9916Q30244524-A4631725-BBD7-43D5-8942-993BABFFD3FDQ30252014-62F2EE15-CB9B-4FC3-B073-FD604A5E6774Q30841523-D7439B4B-6549-4E3E-A8D1-5343D99D829EQ35790918-F2A53C8B-988C-4233-A65F-BE094FDE5B49Q38263296-6DB3A121-4758-48F9-8264-F655181388A8Q38395133-623D9FAA-30B8-464C-8600-6C1EA57D515FQ38663661-6EF7ED89-975A-45BB-A5F6-D4394343860FQ38683084-87C072FF-42BE-41C2-BC87-4824F32DF218Q38788011-CC9A5DCA-C7CE-4725-A11A-B97CE2DC3F49Q38830272-026E8192-4FC2-4E4C-81B7-AD0E2FDC0957Q38835405-B163F45A-031B-4F18-8AEA-E9C75974AF09Q38996435-8A8F0134-6801-4835-A4B0-EB36530EC365Q39262123-0CE00810-C2A4-4034-88EA-862CF1FF00F3Q40130519-5573D1AF-D0F9-4DDF-AD8B-2B3893769948Q40157001-82274472-D01E-446D-8965-5F8C290D351FQ40160990-E1D9B0D6-4E0B-4E5A-B511-30B2B7CE926BQ40207332-9919C741-AF9F-4DDD-B01B-76D8497AD6A3Q40246531-8EAF2E4D-CF85-436B-BBB2-EF618124133CQ40732423-9E89EAB7-E77A-45AD-BF74-7FB67940A3BFQ41138186-CDA21A7D-0920-4C77-A850-5499AF92DD35Q45075955-D5CDE963-D78E-43BE-BEA2-AEDEAC25C07CQ47353417-1E4CC14A-A1FF-442F-B3CC-642883EA128AQ47777858-442F254C-B504-4608-BECA-D10577F1A3DCQ51322315-259FA389-3029-4461-A656-C5895C02F5DB
P2860
Understanding the costs of care for cystic fibrosis: an analysis by age and health state.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Understanding the costs of care for cystic fibrosis: an analysis by age and health state.
@en
Understanding the costs of care for cystic fibrosis: an analysis by age and health state.
@nl
type
label
Understanding the costs of care for cystic fibrosis: an analysis by age and health state.
@en
Understanding the costs of care for cystic fibrosis: an analysis by age and health state.
@nl
prefLabel
Understanding the costs of care for cystic fibrosis: an analysis by age and health state.
@en
Understanding the costs of care for cystic fibrosis: an analysis by age and health state.
@nl
P50
P1433
P1476
Understanding the costs of care for cystic fibrosis: an analysis by age and health state.
@en
P2093
John Massie
Martin B Delatycki
P304
P356
10.1016/J.JVAL.2012.12.003
P577
2013-03-01T00:00:00Z